Exscientia - Exscientia plc (Nasdaq: EXAI) today filed the attached ...
OXFORD, England (13 February, 2024) - Exscientia plc (Nasdaq: EXAI) today filed the attached disclosure to the U.S. Securities and Exchange Commission (SEC).
Exscientia - Recursion and Exscientia Enter Definitive Agreement to ...
Aug 8, 2024 · SALT LAKE CITY and OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today …
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 ...
Jul 18, 2024 · OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 …
Exscientia - Exscientia Announces AI Drug Discovery Collaboration …
Sep 20, 2023 · OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the …
Investor Relations - Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with …
Exscientia announces multi-target, AI-driven drug discovery ...
May 19, 2021 · Upfront and potential milestones of over $1.2bn in addition to tiered royalties Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, …
Recursion and Exscientia Shareholders Approve the Proposed …
Nov 13, 2024 · Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming …
Exscientia - Exscientia Announces Closing of $510.4 Million …
Oct 5, 2021 · Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective …
Exscientia - Exscientia Announces Pricing of $304.7 Million Upsized ...
Sep 30, 2021 · Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective …
Exscientia - Exscientia Announces Expansion of its Current ...
Dec 21, 2023 · OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially …